Overview

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy

Status:
Not yet recruiting

Trial end date:
2031-08-26

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy, safety, drug levels, and drug effects of ozanimod in pediatric participants with moderately to severely active Crohn's Disease.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Ozanimod